Critical Analysis: Targeted Medical Pharma (OTCMKTS:TRGM) and Taysha Gene Therapies (NASDAQ:TSHA)

Targeted Medical Pharma (OTCMKTS:TRGM) and Taysha Gene Therapies (NASDAQ:TSHA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Targeted Medical Pharma and Taysha Gene Therapies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Targeted Medical Pharma	0	0	0	0	0.00
Taysha Gene Therapies	0	0	8	0	3.00

Taysha Gene Therapies has a consensus price target of $8.2857, suggesting a potential upside of 182.79%. Given Taysha Gene Therapies’ stronger consensus rating and higher probable upside, analysts clearly believe Taysha Gene Therapies is more favorable than Targeted Medical Pharma.

Profitability

This table compares Targeted Medical Pharma and Taysha Gene Therapies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Targeted Medical Pharma	N/A	N/A	N/A
Taysha Gene Therapies	-1,144.97%	-78.44%	-44.82%

Insider & Institutional Ownership

77.7% of Taysha Gene Therapies shares are owned by institutional investors. 69.2% of Targeted Medical Pharma shares are owned by insiders. Comparatively, 3.8% of Taysha Gene Therapies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Targeted Medical Pharma and Taysha Gene Therapies”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Targeted Medical Pharma	N/A	N/A	N/A	N/A	N/A
Taysha Gene Therapies	$8.33 million	75.50	-$89.30 million	($0.34)	-8.62

Targeted Medical Pharma has higher earnings, but lower revenue than Taysha Gene Therapies.

Summary

Taysha Gene Therapies beats Targeted Medical Pharma on 5 of the 9 factors compared between the two stocks.

About Targeted Medical Pharma

Targeted Medical Pharma, Inc., a specialty pharmaceutical company, doing business as Physician Therapeutics, develops and commercializes amino acid based medications to physicians, pharmacies, and patients in the United States. It offers a line of patented amino acid based medical food products, dietary supplements, and generic drugs primarily for the treatment of metabolic syndrome/obesity; sleep disorders associated with anxiety; hypertension; viral infections; cognitive disorders/fatigue; sleep disorders associated with depression, fibromyalgia, and PTSD; pain disorders and inflammatory conditions/fibromyalgia; osteoarthritis and joint disorders; and peripheral neuropathy. The company also provides a proprietary billing process and supporting software (PDRx) that facilitates physician dispensing; provides inventory control; and assists regulatory reporting. In addition, it offers billing and collection services relating to its products on behalf of dispensing physician clients to private insurance and workers' compensation insurance. Targeted Medical Pharma, Inc. distributes its products through a network of distributors and an internal sales force that sells products directly to dispensing physician clients. The company was formerly known as Targeted Medical Foods and changed its name to Targeted Medical Pharma, Inc. in 2006. Targeted Medical Pharma, Inc. was founded in 1996 and is headquartered in Los Angeles, California.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.